BR9814106A - Processo para tratar da esquizofrenia em um indivìduo, e, conjunto - Google Patents

Processo para tratar da esquizofrenia em um indivìduo, e, conjunto

Info

Publication number
BR9814106A
BR9814106A BR9814106-6A BR9814106A BR9814106A BR 9814106 A BR9814106 A BR 9814106A BR 9814106 A BR9814106 A BR 9814106A BR 9814106 A BR9814106 A BR 9814106A
Authority
BR
Brazil
Prior art keywords
schizophrenia
individual
treatment
relates
treat schizophrenia
Prior art date
Application number
BR9814106-6A
Other languages
English (en)
Inventor
Steven A Johnson
Gary A Rogers
Gary S Lynch
Original Assignee
Cortex Pharma Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22050462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9814106(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cortex Pharma Inc, Univ California filed Critical Cortex Pharma Inc
Publication of BR9814106A publication Critical patent/BR9814106A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"PROCESSO PARA TRATAR DA ESQUIZOFRENIA EM UM INDIVìDUO, E, CONJUNTO" Esta invenção diz respeito ao tratamento da esquizofrenia e distúrbios psicóticos relacionados, incluindo a intensificação do funcionamento receptor nas sinapses nas redes cerebrais responsáveis por comportamentos de ordem mais elevada. Em um aspecto particular, a invenção diz respeito a processos para o uso de supra-moduladores do receptor AMPA em conjunção com antipsicóticos para o tratamento da esquizofrenia. Conjuntos contendo as composições na forma apropriada para administração também são fornecidos. A figura mostra que uma Ampacina (CX516) representativa intensifica sinergisticamente o antagonismo da clozapina de atividade de estímulo induzida pela metanfetamina.
BR9814106-6A 1997-10-27 1998-10-26 Processo para tratar da esquizofrenia em um indivìduo, e, conjunto BR9814106A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6362797P 1997-10-27 1997-10-27
PCT/US1998/022707 WO1999021422A1 (en) 1997-10-27 1998-10-26 Treatment of schizophrenia with ampakines and neuroleptics

Publications (1)

Publication Number Publication Date
BR9814106A true BR9814106A (pt) 2000-10-03

Family

ID=22050462

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814106-6A BR9814106A (pt) 1997-10-27 1998-10-26 Processo para tratar da esquizofrenia em um indivìduo, e, conjunto

Country Status (15)

Country Link
US (1) US6166008A (pt)
EP (1) EP1026950B1 (pt)
JP (1) JP2001520978A (pt)
CN (1) CN1281335A (pt)
AT (1) ATE317226T1 (pt)
AU (1) AU745641B2 (pt)
BR (1) BR9814106A (pt)
CA (1) CA2306817A1 (pt)
CY (1) CY1105557T1 (pt)
DE (1) DE69833451T2 (pt)
DK (1) DK1026950T3 (pt)
ES (1) ES2258825T3 (pt)
HK (1) HK1030338A1 (pt)
PT (1) PT1026950E (pt)
WO (1) WO1999021422A1 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450801C (en) 1992-07-24 2009-11-17 The Regent Of The University Of California Drugs that enhance synaptic responses mediated by ampa receptors
WO2002096431A1 (en) * 2001-05-25 2002-12-05 The Regents Of The University Of California Optically active compounds clearing malformed proteins
US20040229898A1 (en) * 2001-05-25 2004-11-18 The Regents Of The University Of California Cyclic bis-compounds clearing malformed proteins
JP2004538323A (ja) * 2001-08-10 2004-12-24 ザ ロックフェラー ユニバーシティー Ｄａｒｐｐ−３２リン酸化のモジュレーションのための組成物及び方法
US20060276462A1 (en) * 2003-01-13 2006-12-07 Deadwyler Sam A Method of treating cognitive decline due to sleep deprivation and stress
WO2005013961A1 (en) * 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
JP2007504136A (ja) 2003-08-28 2007-03-01 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化利尿化合物、組成物、ならびに使用方法
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
JP2007519733A (ja) * 2004-01-26 2007-07-19 コーテックス ファーマシューティカルズ インコーポレーティッド アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
EP2453024B1 (en) 2004-06-21 2017-12-06 The Board of Trustees of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
WO2006034196A1 (en) * 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
EP1809104A4 (en) * 2004-09-23 2009-04-29 Alexander Michalow METHODS FOR REGULATING NEUROTRANSMITTER SYSTEMS BY INDUCING COUNTER-ADAPTATIONS
EP1855688A4 (en) * 2005-02-24 2011-09-14 Nicox Sa NON-STAINED OXIDE DIURETIC COMPOUNDS, COMPOSITIONS AND USE PROCESSES
TWI378090B (en) 2005-04-13 2012-12-01 Astex Therapeutics Ltd Pharmaceutical compounds
KR20060119373A (ko) * 2005-05-20 2006-11-24 엘지전자 주식회사 컴퓨터 시스템과 시스템 소프트웨어 설치방법 및 휴대용컴퓨터의 소프트웨어 설치방법
US20090019557A1 (en) 2005-11-12 2009-01-15 Huda Akil Fgf2-related methods for diagnosing and treating depression
US20090286797A1 (en) * 2005-11-22 2009-11-19 Dan Peters Novel Quinoxaline Derivatives and Their Medical Use
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US20080176793A1 (en) * 2006-09-18 2008-07-24 The Regents Of The University Of California Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044027A2 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical compounds having hsp90 inhibitory or modulating activity
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US20090006902A1 (en) * 2007-06-29 2009-01-01 International Business Machines Corporation Methods, systems, and computer program products for reporting fru failures in storage device enclosures
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8263591B2 (en) 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
WO2010087980A2 (en) * 2009-02-02 2010-08-05 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory depression
PT105083A (pt) 2009-04-28 2011-07-25 Univ De Coimbra Processo para cultura de células estaminais neurais baseado nas ampacinas e/ou outros moduladores de receptores glutamatérgicos ionotrópicos, composições e seu uso em condições do sistema nervoso central
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US9700596B2 (en) 2011-03-04 2017-07-11 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) * 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
ES2673872T3 (es) 2012-06-05 2018-06-26 The Board Of Trustees Of The Leland Stanford Junior University Mimético del péptido NCAM para su uso en el tratamiento de trastorno de depresión mayor
UA127357C2 (uk) 2018-04-18 2023-07-26 Констеллатіон Фармацеутікалс, Інк. Модулятори метилмодифікуючих ферментів, композиції та їх використання
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
US5447948A (en) * 1992-05-07 1995-09-05 Yale University Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
GB9507230D0 (en) * 1995-04-07 1995-05-31 Inst Of Psychiatry Novel method
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5773434A (en) * 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response

Also Published As

Publication number Publication date
DE69833451D1 (de) 2006-04-20
DE69833451T2 (de) 2006-09-28
HK1030338A1 (en) 2001-05-04
CN1281335A (zh) 2001-01-24
CA2306817A1 (en) 1999-05-06
ATE317226T1 (de) 2006-02-15
WO1999021422A1 (en) 1999-05-06
EP1026950A4 (en) 2004-07-07
US6166008A (en) 2000-12-26
DK1026950T3 (da) 2006-06-26
EP1026950B1 (en) 2006-02-08
PT1026950E (pt) 2006-06-30
AU1365899A (en) 1999-05-17
ES2258825T3 (es) 2006-09-01
EP1026950A1 (en) 2000-08-16
AU745641B2 (en) 2002-03-28
CY1105557T1 (el) 2010-07-28
JP2001520978A (ja) 2001-11-06

Similar Documents

Publication Publication Date Title
BR9814106A (pt) Processo para tratar da esquizofrenia em um indivìduo, e, conjunto
BR9914109A (pt) Composições antibióticas para tratamento dos olhos, ouvidos e nariz
BR9914151A (pt) Composições antibióticas para tratamento dos olhos, ouvidos e nariz
ES2152556T3 (es) Composiciones que contienen derivados del acido hidroperoxieicosatetraenoico y procedimientos de utilizacion en el tratamiento de trastornos de la sequedad ocular.
UY26130A1 (es) Compuestos para tratar la obesidad
NO306779B1 (no) Naftalamider, anvendelse derav og farmasöytisk preparat
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR0108611A (pt) Moduladores de receptor de adenosina
BRPI0502346A (pt) processo de tratamento cosmético para prevenir e/ou tratar as peles sensìveis e/ou secas, utilização de uma quantidade eficaz de pelo menos um microorganismo notadamente probiótico e/ou uma de suas frações e/ou um de seus metabólitos e composição cosméticas e/ou dermatológica
PT1052905E (pt) Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol
BRPI0412262A (pt) derivados de azepina como agentes farmacêuticos
BR0314353A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio
BR9808077A (pt) Combinação, formulação farmacêutica, processo para o tratamento de um distúrbio psicótico em um aninal, usos de mirtazapina e de um agente antipsicótico, e, pacote para paciente
NZ505742A (en) Compositions containing aminobiguanides with antimicrobial activity used to treat contact lenses
BR9914128A (pt) Composições antibióticas para tratamento do olho, ouvido e nariz
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
BR9708287A (pt) Processo para tratar ou prevenir um distúrbio do sistema nervoso central em um ser humano, para eliciar um efeito antiemético em um ser humano e para tratar um estado de doença em um ser humano, composição farmacêutica para tratar de distúrbios do sistema nervoso central em um ser humano, e, forma de dosagem unitária farmacêutica
BR0208353A (pt) Compostos de diidropirimidina substituìdos com ciano e seu uso para tratar doenças
MX232591B (es) Procedimiento para tratar infecciones oculares con azitromicina
ATE318610T1 (de) Orale zusammensetzungen zur behandlung von kopfhauterkrankungen
BR0013637A (pt) Método para formar uma fibra tratada e fibra tratada formada a partir de tal método
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
BRPI0410654A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR9911559A (pt) Processo para a preparação de um composto, composto, processo para o tratamento de tumores resistentes a medicamento múltiplo, uso de um composto, e, agente e composição para tratar tumores resistentes a medicamento múltiplo.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.